18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer
Background Colorectal cancer (CRC) is one of the most widespread cancers worldwide, leading to roughly half a million deaths yearly. The European Society for Medical Oncology defined oligometastatic CRC as a disease with few metastases affecting a small number of sites (5 or occasionally more metast...
Gespeichert in:
| Veröffentlicht in: | Egyptian Journal of Radiology and Nuclear Medicine 2023-12, Vol.54 (1), p.33-11, Article 33 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | Egyptian Journal of Radiology and Nuclear Medicine |
| container_volume | 54 |
| creator | Nasr, Ibrahim Mansour Maksoud, Bader Abdel Rezk, Mahmoud Ali Badawy, Ahmed Almorsy, Walid Ahmed Ali, Ismail Mohamed |
| description | Background
Colorectal cancer (CRC) is one of the most widespread cancers worldwide, leading to roughly half a million deaths yearly. The European Society for Medical Oncology defined oligometastatic CRC as a disease with few metastases affecting a small number of sites (5 or occasionally more metastases involving up to 3 sites). In addition to colonoscopy, magnetic resonance imaging (MRI), and digital rectal examination in patients with rectal cancer, response monitoring of CRC is commonly carried out by CT imaging. The use of PET for response monitoring has not been adapted into colorectal cancer guidelines until 2021. However, 18F-Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18F-FDG PET/CT) offers a higher efficiency for assessing treatment outcomes than traditional imaging. This study aims to explore the utility of 18F-FDG PET/CT imaging in the assessment of therapy response in patients with oligometastatic colorectal cancer (OMCRC).
Results
The study comprised 79 OMCRC patients (35 and 44 patients with synchronous and metachronous metastasis respectively). In synchronous disease patients 18F-FDG PET/CT scan showed significant reduction of mean size and standardized uptake value (SUV) of the primary site lesions and the mean SUV of lymph nodes (LNs) and lung metastases (
P
= 0.00, 0.00,0.00, and 0.002, respectively) while, metachronous disease patients had significant reduction in the mean size and SUV of LNs (1.8 ± 0.7 & 4.7 ± 1.3 versus 1.1 ± 1.0 & 2.9 ± 3.0,
P
= 0.001 & 0.00 respectively) and the mean SUV of peritoneal metastases (8.7 ± 4.7 versus 6.8 ± 2.4
P
= 0.00). Partial metabolic response (PMR) and stable metabolic disease (SMD) were found in more than half of the patients (58.2%). Complete metabolic response (CMR) and Progressive metabolic disease (PMD), on the other hand, were achieved in 41.8% of patients [17 (21.5%) and 16 (20.3%) patients, respectively] with substantially higher CMR rate in metachronous disease than synchronous disease [14.0 (31.8%) versus 3.0 (8.5%) patients,
P
= 0.015)].
Conclusions
18F-FDG PET/CT can be added as a valuable imaging method for identifying responders and non-responders among OMCRC patients, as it optimizes the selection of patients with CRC for local therapy and has a significant impact on directing their therapy course. Oligometastatic colorectal cancer seems to be a controllable disease with hopeful therapy outcomes, particularly for those with metachronous metastases. |
| doi_str_mv | 10.1186/s43055-023-00961-x |
| format | Article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_proquest_journals_2774730415</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A736516952</galeid><doaj_id>oai_doaj_org_article_f99ea77b29434b569ea013e1e24e2554</doaj_id><sourcerecordid>A736516952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-3d03368833b39cb7bfdb6f24f9e38d8b61924aae93702d0694335ba8c09abeee3</originalsourceid><addsrcrecordid>eNp9kc1q3DAUhU1poSHJC3Rl6NqJ_mV1F6aZNBBIFtO1uJKvpxpsayopkLx91bg0LZRKC0mX8x2OOE3zgZILSnt1mQUnUnaE8Y4Qo2j39KY5YcSQTmjF3v5xf9-c53wgdQlCqBInzQPtt9328037cL273OzasLTlGyY4PrcJ8zEuGVvIGXOecSmf2jiFfZyxQC5Qgm99nGJCX2BqPSwe01nzboQp4_mv87T5ur3ebb50d_c3t5uru84LoUvHB8K56nvOHTfeaTcOTo1MjAZ5P_ROUcMEABquCRuIMoJz6aD3xIBDRH7a3K6-Q4SDPaYwQ3q2EYJ9GcS0t5BqwgntaAyC1o5VE-Gkqi9COVJkApmUonp9XL2OKX5_xFzsIT6mpca3TGuhORFUvqr2UE3DMsaSwM8he3uluZJUGcmq6uIfqroHnIOPC46hzv8C2Ar4FHNOOP7-DCX2Z7927dfWfu1Lv_apQnyFchUve0yvif9D_QCb1aU1</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2774730415</pqid></control><display><type>article</type><title>18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer</title><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Nasr, Ibrahim Mansour ; Maksoud, Bader Abdel ; Rezk, Mahmoud Ali ; Badawy, Ahmed ; Almorsy, Walid Ahmed ; Ali, Ismail Mohamed</creator><creatorcontrib>Nasr, Ibrahim Mansour ; Maksoud, Bader Abdel ; Rezk, Mahmoud Ali ; Badawy, Ahmed ; Almorsy, Walid Ahmed ; Ali, Ismail Mohamed</creatorcontrib><description>Background
Colorectal cancer (CRC) is one of the most widespread cancers worldwide, leading to roughly half a million deaths yearly. The European Society for Medical Oncology defined oligometastatic CRC as a disease with few metastases affecting a small number of sites (5 or occasionally more metastases involving up to 3 sites). In addition to colonoscopy, magnetic resonance imaging (MRI), and digital rectal examination in patients with rectal cancer, response monitoring of CRC is commonly carried out by CT imaging. The use of PET for response monitoring has not been adapted into colorectal cancer guidelines until 2021. However, 18F-Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18F-FDG PET/CT) offers a higher efficiency for assessing treatment outcomes than traditional imaging. This study aims to explore the utility of 18F-FDG PET/CT imaging in the assessment of therapy response in patients with oligometastatic colorectal cancer (OMCRC).
Results
The study comprised 79 OMCRC patients (35 and 44 patients with synchronous and metachronous metastasis respectively). In synchronous disease patients 18F-FDG PET/CT scan showed significant reduction of mean size and standardized uptake value (SUV) of the primary site lesions and the mean SUV of lymph nodes (LNs) and lung metastases (
P
= 0.00, 0.00,0.00, and 0.002, respectively) while, metachronous disease patients had significant reduction in the mean size and SUV of LNs (1.8 ± 0.7 & 4.7 ± 1.3 versus 1.1 ± 1.0 & 2.9 ± 3.0,
P
= 0.001 & 0.00 respectively) and the mean SUV of peritoneal metastases (8.7 ± 4.7 versus 6.8 ± 2.4
P
= 0.00). Partial metabolic response (PMR) and stable metabolic disease (SMD) were found in more than half of the patients (58.2%). Complete metabolic response (CMR) and Progressive metabolic disease (PMD), on the other hand, were achieved in 41.8% of patients [17 (21.5%) and 16 (20.3%) patients, respectively] with substantially higher CMR rate in metachronous disease than synchronous disease [14.0 (31.8%) versus 3.0 (8.5%) patients,
P
= 0.015)].
Conclusions
18F-FDG PET/CT can be added as a valuable imaging method for identifying responders and non-responders among OMCRC patients, as it optimizes the selection of patients with CRC for local therapy and has a significant impact on directing their therapy course. Oligometastatic colorectal cancer seems to be a controllable disease with hopeful therapy outcomes, particularly for those with metachronous metastases.</description><identifier>ISSN: 2090-4762</identifier><identifier>ISSN: 0378-603X</identifier><identifier>EISSN: 2090-4762</identifier><identifier>DOI: 10.1186/s43055-023-00961-x</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Bladder ; Cancer therapies ; Colonoscopy ; Colorectal cancer ; Colorectal neoplasms ; CT imaging ; Diabetes ; Disease ; Fluorodeoxyglucose F18 positron emission tomography ; Follow-up studies ; Hydration ; Imaging ; Laboratories ; Medical imaging ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Metabolic disorders ; Metastasis ; Nuclear Medicine ; PET imaging ; Radiation ; Radiology ; Sport-utility vehicles</subject><ispartof>Egyptian Journal of Radiology and Nuclear Medicine, 2023-12, Vol.54 (1), p.33-11, Article 33</ispartof><rights>The Author(s) 2023</rights><rights>COPYRIGHT 2023 Springer</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c447t-3d03368833b39cb7bfdb6f24f9e38d8b61924aae93702d0694335ba8c09abeee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27923,27924</link.rule.ids></links><search><creatorcontrib>Nasr, Ibrahim Mansour</creatorcontrib><creatorcontrib>Maksoud, Bader Abdel</creatorcontrib><creatorcontrib>Rezk, Mahmoud Ali</creatorcontrib><creatorcontrib>Badawy, Ahmed</creatorcontrib><creatorcontrib>Almorsy, Walid Ahmed</creatorcontrib><creatorcontrib>Ali, Ismail Mohamed</creatorcontrib><title>18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer</title><title>Egyptian Journal of Radiology and Nuclear Medicine</title><addtitle>Egypt J Radiol Nucl Med</addtitle><description>Background
Colorectal cancer (CRC) is one of the most widespread cancers worldwide, leading to roughly half a million deaths yearly. The European Society for Medical Oncology defined oligometastatic CRC as a disease with few metastases affecting a small number of sites (5 or occasionally more metastases involving up to 3 sites). In addition to colonoscopy, magnetic resonance imaging (MRI), and digital rectal examination in patients with rectal cancer, response monitoring of CRC is commonly carried out by CT imaging. The use of PET for response monitoring has not been adapted into colorectal cancer guidelines until 2021. However, 18F-Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18F-FDG PET/CT) offers a higher efficiency for assessing treatment outcomes than traditional imaging. This study aims to explore the utility of 18F-FDG PET/CT imaging in the assessment of therapy response in patients with oligometastatic colorectal cancer (OMCRC).
Results
The study comprised 79 OMCRC patients (35 and 44 patients with synchronous and metachronous metastasis respectively). In synchronous disease patients 18F-FDG PET/CT scan showed significant reduction of mean size and standardized uptake value (SUV) of the primary site lesions and the mean SUV of lymph nodes (LNs) and lung metastases (
P
= 0.00, 0.00,0.00, and 0.002, respectively) while, metachronous disease patients had significant reduction in the mean size and SUV of LNs (1.8 ± 0.7 & 4.7 ± 1.3 versus 1.1 ± 1.0 & 2.9 ± 3.0,
P
= 0.001 & 0.00 respectively) and the mean SUV of peritoneal metastases (8.7 ± 4.7 versus 6.8 ± 2.4
P
= 0.00). Partial metabolic response (PMR) and stable metabolic disease (SMD) were found in more than half of the patients (58.2%). Complete metabolic response (CMR) and Progressive metabolic disease (PMD), on the other hand, were achieved in 41.8% of patients [17 (21.5%) and 16 (20.3%) patients, respectively] with substantially higher CMR rate in metachronous disease than synchronous disease [14.0 (31.8%) versus 3.0 (8.5%) patients,
P
= 0.015)].
Conclusions
18F-FDG PET/CT can be added as a valuable imaging method for identifying responders and non-responders among OMCRC patients, as it optimizes the selection of patients with CRC for local therapy and has a significant impact on directing their therapy course. Oligometastatic colorectal cancer seems to be a controllable disease with hopeful therapy outcomes, particularly for those with metachronous metastases.</description><subject>Bladder</subject><subject>Cancer therapies</subject><subject>Colonoscopy</subject><subject>Colorectal cancer</subject><subject>Colorectal neoplasms</subject><subject>CT imaging</subject><subject>Diabetes</subject><subject>Disease</subject><subject>Fluorodeoxyglucose F18 positron emission tomography</subject><subject>Follow-up studies</subject><subject>Hydration</subject><subject>Imaging</subject><subject>Laboratories</subject><subject>Medical imaging</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Metabolic disorders</subject><subject>Metastasis</subject><subject>Nuclear Medicine</subject><subject>PET imaging</subject><subject>Radiation</subject><subject>Radiology</subject><subject>Sport-utility vehicles</subject><issn>2090-4762</issn><issn>0378-603X</issn><issn>2090-4762</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNp9kc1q3DAUhU1poSHJC3Rl6NqJ_mV1F6aZNBBIFtO1uJKvpxpsayopkLx91bg0LZRKC0mX8x2OOE3zgZILSnt1mQUnUnaE8Y4Qo2j39KY5YcSQTmjF3v5xf9-c53wgdQlCqBInzQPtt9328037cL273OzasLTlGyY4PrcJ8zEuGVvIGXOecSmf2jiFfZyxQC5Qgm99nGJCX2BqPSwe01nzboQp4_mv87T5ur3ebb50d_c3t5uru84LoUvHB8K56nvOHTfeaTcOTo1MjAZ5P_ROUcMEABquCRuIMoJz6aD3xIBDRH7a3K6-Q4SDPaYwQ3q2EYJ9GcS0t5BqwgntaAyC1o5VE-Gkqi9COVJkApmUonp9XL2OKX5_xFzsIT6mpca3TGuhORFUvqr2UE3DMsaSwM8he3uluZJUGcmq6uIfqroHnIOPC46hzv8C2Ar4FHNOOP7-DCX2Z7927dfWfu1Lv_apQnyFchUve0yvif9D_QCb1aU1</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Nasr, Ibrahim Mansour</creator><creator>Maksoud, Bader Abdel</creator><creator>Rezk, Mahmoud Ali</creator><creator>Badawy, Ahmed</creator><creator>Almorsy, Walid Ahmed</creator><creator>Ali, Ismail Mohamed</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><general>SpringerOpen</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope></search><sort><creationdate>20231201</creationdate><title>18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer</title><author>Nasr, Ibrahim Mansour ; Maksoud, Bader Abdel ; Rezk, Mahmoud Ali ; Badawy, Ahmed ; Almorsy, Walid Ahmed ; Ali, Ismail Mohamed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-3d03368833b39cb7bfdb6f24f9e38d8b61924aae93702d0694335ba8c09abeee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Bladder</topic><topic>Cancer therapies</topic><topic>Colonoscopy</topic><topic>Colorectal cancer</topic><topic>Colorectal neoplasms</topic><topic>CT imaging</topic><topic>Diabetes</topic><topic>Disease</topic><topic>Fluorodeoxyglucose F18 positron emission tomography</topic><topic>Follow-up studies</topic><topic>Hydration</topic><topic>Imaging</topic><topic>Laboratories</topic><topic>Medical imaging</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Metabolic disorders</topic><topic>Metastasis</topic><topic>Nuclear Medicine</topic><topic>PET imaging</topic><topic>Radiation</topic><topic>Radiology</topic><topic>Sport-utility vehicles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nasr, Ibrahim Mansour</creatorcontrib><creatorcontrib>Maksoud, Bader Abdel</creatorcontrib><creatorcontrib>Rezk, Mahmoud Ali</creatorcontrib><creatorcontrib>Badawy, Ahmed</creatorcontrib><creatorcontrib>Almorsy, Walid Ahmed</creatorcontrib><creatorcontrib>Ali, Ismail Mohamed</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Egyptian Journal of Radiology and Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nasr, Ibrahim Mansour</au><au>Maksoud, Bader Abdel</au><au>Rezk, Mahmoud Ali</au><au>Badawy, Ahmed</au><au>Almorsy, Walid Ahmed</au><au>Ali, Ismail Mohamed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer</atitle><jtitle>Egyptian Journal of Radiology and Nuclear Medicine</jtitle><stitle>Egypt J Radiol Nucl Med</stitle><date>2023-12-01</date><risdate>2023</risdate><volume>54</volume><issue>1</issue><spage>33</spage><epage>11</epage><pages>33-11</pages><artnum>33</artnum><issn>2090-4762</issn><issn>0378-603X</issn><eissn>2090-4762</eissn><abstract>Background
Colorectal cancer (CRC) is one of the most widespread cancers worldwide, leading to roughly half a million deaths yearly. The European Society for Medical Oncology defined oligometastatic CRC as a disease with few metastases affecting a small number of sites (5 or occasionally more metastases involving up to 3 sites). In addition to colonoscopy, magnetic resonance imaging (MRI), and digital rectal examination in patients with rectal cancer, response monitoring of CRC is commonly carried out by CT imaging. The use of PET for response monitoring has not been adapted into colorectal cancer guidelines until 2021. However, 18F-Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18F-FDG PET/CT) offers a higher efficiency for assessing treatment outcomes than traditional imaging. This study aims to explore the utility of 18F-FDG PET/CT imaging in the assessment of therapy response in patients with oligometastatic colorectal cancer (OMCRC).
Results
The study comprised 79 OMCRC patients (35 and 44 patients with synchronous and metachronous metastasis respectively). In synchronous disease patients 18F-FDG PET/CT scan showed significant reduction of mean size and standardized uptake value (SUV) of the primary site lesions and the mean SUV of lymph nodes (LNs) and lung metastases (
P
= 0.00, 0.00,0.00, and 0.002, respectively) while, metachronous disease patients had significant reduction in the mean size and SUV of LNs (1.8 ± 0.7 & 4.7 ± 1.3 versus 1.1 ± 1.0 & 2.9 ± 3.0,
P
= 0.001 & 0.00 respectively) and the mean SUV of peritoneal metastases (8.7 ± 4.7 versus 6.8 ± 2.4
P
= 0.00). Partial metabolic response (PMR) and stable metabolic disease (SMD) were found in more than half of the patients (58.2%). Complete metabolic response (CMR) and Progressive metabolic disease (PMD), on the other hand, were achieved in 41.8% of patients [17 (21.5%) and 16 (20.3%) patients, respectively] with substantially higher CMR rate in metachronous disease than synchronous disease [14.0 (31.8%) versus 3.0 (8.5%) patients,
P
= 0.015)].
Conclusions
18F-FDG PET/CT can be added as a valuable imaging method for identifying responders and non-responders among OMCRC patients, as it optimizes the selection of patients with CRC for local therapy and has a significant impact on directing their therapy course. Oligometastatic colorectal cancer seems to be a controllable disease with hopeful therapy outcomes, particularly for those with metachronous metastases.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1186/s43055-023-00961-x</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2090-4762 |
| ispartof | Egyptian Journal of Radiology and Nuclear Medicine, 2023-12, Vol.54 (1), p.33-11, Article 33 |
| issn | 2090-4762 0378-603X 2090-4762 |
| language | eng |
| recordid | cdi_proquest_journals_2774730415 |
| source | DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Bladder Cancer therapies Colonoscopy Colorectal cancer Colorectal neoplasms CT imaging Diabetes Disease Fluorodeoxyglucose F18 positron emission tomography Follow-up studies Hydration Imaging Laboratories Medical imaging Medical research Medicine Medicine & Public Health Medicine, Experimental Metabolic disorders Metastasis Nuclear Medicine PET imaging Radiation Radiology Sport-utility vehicles |
| title | 18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T02%3A08%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=18F-FDG%20PET/CT%20in%20therapy%20response%20assessment:%20oligometastatic%20colorectal%20cancer&rft.jtitle=Egyptian%20Journal%20of%20Radiology%20and%20Nuclear%20Medicine&rft.au=Nasr,%20Ibrahim%20Mansour&rft.date=2023-12-01&rft.volume=54&rft.issue=1&rft.spage=33&rft.epage=11&rft.pages=33-11&rft.artnum=33&rft.issn=2090-4762&rft.eissn=2090-4762&rft_id=info:doi/10.1186/s43055-023-00961-x&rft_dat=%3Cgale_doaj_%3EA736516952%3C/gale_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2774730415&rft_id=info:pmid/&rft_galeid=A736516952&rft_doaj_id=oai_doaj_org_article_f99ea77b29434b569ea013e1e24e2554&rfr_iscdi=true |